Clinical trials: Cerebrovascular Disorder
Stroke, Prevention and Control
An Observational Cross-sectional Study Evaluating the Use of Re-sources and the Sociodemographic and Clinical Characteristics of Patients Diagnosed With Non-valvular Atrial Fibrillation With a Risk of Stroke or Systemic Embolism on Anticoagulant Therapy and Treated in Primary Care Centers
This is a retrospective observational study to describe the sociodemographic and clinical characteristics of patients diagnosed with non-valvular atrial fibrillation (NVAF) at risk of stroke or systemic embolism, who at least…
- Conditions
- Stroke, Prevention and Control, Atrial Fibrillation
- Trial name
- BRONCE-AP (NCT02559232)
- Testing
- Direct Oral Anticoagulant (DOAC)
- Where
- Spain
- Volunteers
- 247 people
- Sponsor
- Bayer
Ischemic Stroke
EMAGINE 2.0 - Electromagnetic Field Ischemic Stroke - Novel Subacute Treatment
This is a multicenter study that will be conducted at approximately 20 centers and up to 30 centers, if the sample size will be increased following interim assessment.
- Trial name
- NCT06386874
- Testing
- Q Therapeutic System (BQ 3.0) - Active
- Where
- 14 sites in United States
- Volunteers
- 122 people
- Sponsor
- BrainQ Technologies Ltd.
Cardiovascular Disease, Cerebrovascular Accident
A Study to Determine the Degree of Additional Reduction in CV Risk in Lowering LDL Below Minimum Target Levels
The primary objective of this study is to determine the degree of additional reduction in cardiovascular risk that was accrued to patients by lowering their LDL-C beyond the currently accepted minimum target level for patients…
- Conditions
- Cardiovascular Disease, Cerebrovascular Accident, Coronary Heart Disease
- Trial name
- TNT (NCT00327691)
- Testing
- Atorvastatin
- Where
- 314 sites in United States, Australia and 12 more
- Volunteers
- 8,600 people
- Sponsor
- Pfizer
Intracranial Aneurysm
Safety and Performance of the Neuroform Atlas™ Stent System
The objective of this retrospective study is to describe in real-life settings the clinical practice, utilization and the treated population outcomes at 1-year (12-16 months) follow-up at selected, representative centers in…
- Trial name
- ATLAS-FR (NCT04162483)
- Testing
- Neuroform Atlas Stent System
- Where
- France
- Volunteers
- 310 people
- Sponsor
- Stryker Neurovascular
Ischemic Stroke
A Study of NCS-01 in Patients With Acute Ischemic Stroke
This is an initial Phase1/2 dose-finding, randomized, multi-center study to evaluate the safety and tolerability of NCS-01 in patients with acute ischemic stroke. All patients will be randomized within 48 hours of stroke onset.
- Trial name
- NCT03915431
- Testing
- NCS-01
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- NC Medial Research Inc
Ischemic Stroke
A Study of Survival and Outcome After Stroke
The objective of this study is to determine the natural history of acute ischemic stroke from large vessel thromboembolism in the brain.
- Trial name
- SOS (NCT01193569)
- Where
- United Kingdom
- Volunteers
- 142 people
- Sponsor
- Penumbra Inc.
Acute Ischemic Stroke
A Study to Evaluate the Safety and Efficacy of Multiple Doses of LT3001 Drug Product in AIS Subjects
This is a phase II, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of multiple doses of LT3001 drug product in subjects with acute ischemic stroke (AIS)
- Trial name
- BRIGHT (NCT05403866)
- Testing
- LT3001 Drug Product
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- Lumosa Therapeutics Co., Ltd.
Cerebral Infarction
The Safety and Efficacy of Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-ACI) in the Treatment of Acute Cerebral Infarction
The purposes of the study is to determine the safety and efficacy of treating acute ischemic stroke patients with human umbilical cord mesenchymal stem cells (hUC-MSC).
- Trial name
- NCT03186456
- Testing
- Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#), Aspirin Tablet
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sclnow Biotechnology Co., Ltd.
Giant Cell Arteritis (GCA)
A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis
This study consists of two periods. The objective of Period 1 is to evaluate the efficacy of upadacitinib in combination with a 26-week corticosteroid (CS) taper regimen compared to placebo in combination with a 52-week CS taper…
- Trial name
- SELECT-GCA (NCT03725202)
- Testing
- Upadacitinib, Corticosteroid (CS)
- Where
- 172 sites in United States, Australia and 22 more
- Volunteers
- 429 people
- Sponsor
- AbbVie
Stroke, Hemiplegia
Clinical Study to Evaluate the Implantation of the ActiGait Drop Foot Stimulator System
The objective of this study is to evaluate the efficacy and safety of surgical procedure involving ActiGait - implantable drop foot stimulator.
- Trial name
- NCT01116466
- Testing
- ActiGait
- Volunteers
- 5 people
- Sponsor
- Otto Bock Healthcare Products GmbH
Intracranial Aneurysms
Adjunctive Neurovascular Support for Wide-neck Aneurysm Embolization and Reconstruction
This study is designed to evaluate the safety of the PulseRider in patients undergoing treatment for bifurcation basilar or carotid terminus aneurysms.
- Trial name
- ANSWER (NCT02312856)
- Testing
- PulseRider
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Pulsar Vascular
Cerebral Arterial Diseases
Carotid and Vertebral Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF)
The study will evaluate the efficacy and safety of Dotarem enhanced MRA in patients suffering from carotid or vertebral arterial disease.
- Trial name
- NCT01012674
- Testing
- Dotarem, TOF MRA
- Where
- United States
- Volunteers
- 211 people
- Sponsor
- Guerbet
Cerebrovascular Stroke, Large-Artery Atherosclerosis (Embolus/Thrombosis)
A SAD/MAD Study of Safety, Tolerability and Pharmacologic Activity of BT200 in Normal Volunteers
Study BT200-01 is a first in human (FIH) study in male and female normal human volunteers (NHVs) that uses an Integrated Protocol Design.
- Conditions
- Cerebrovascular Stroke, Large-Artery Atherosclerosis (Embolus/Thrombosis), Intracranial Arteriosclerosis
- Trial name
- NCT04103034
- Testing
- BT200, Desmopressin
- Where
- Austria
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Band Therapeutics
Stroke
OASIS STUDY Outcome Assessment Using SF-36 v2 in Stroke Patient Study(OASIS STUDY)
1. To survey the health-related quality of life using the SF-36v2 score of patients with chronic brain infarction in Japan 2. Chronic brain infarction in Japan is better than EU/USA
- Trial name
- NCT00281034
- Where
- Japan
- Volunteers
- 2,069 people
- Sponsor
- Kyorin Pharmaceutical Co.,Ltd
Cerebral Stroke, Thrombosis, Deep Vein
A Study of Adverse Events and Suspected Adverse Drug Reactions in Patients Under Apixaban for Prevention of Stroke and Systemic Embolism With Non-Valvular Atrial Fibrillation and Venous Thromboembolic Events in Patients Who Have Undergone Elective Hip or Knee Replacement Surgery
To characterize and analyze the number, type and incidence of adverse events/suspected adverse drug reactions in patients treated with Apixaban, according to therapeutic indications approved in Mexico.
- Conditions
- Cerebral Stroke, Thrombosis, Deep Vein, Pulmonary Embolism
- Trial name
- NCT03804125
- Sponsor
- Pfizer
Wegener's Granulomatosis or Microscopic Polyangiitis
A Study Evaluating the Safety and Efficacy of Rituximab in Combination With Glucocorticoids in Participants With Wegener's Granulomatosis or Microscopic Polyangitis
This is a perspective, Phase IV, multi-center, single arm, open-label, interventional study in adult participants with Wegener's granulomatosis (granulomatosis with polyangiitis [GPA]) or microscopic polyangiitis.
- Trial name
- NCT02115997
- Testing
- Methylprednisolone, Prednisone, Rituximab
- Where
- 10 sites in India
- Volunteers
- 30 people
- Sponsor
- Hoffmann-La Roche
Acute Ischemic Stroke
A Study of XY03-EA Tablets in the Treatment of Acute Ischemic Stroke
Overall Design: a multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-exploration study. Main outcome: 1.To evaluate the efficacy and safety of XY03-EA tablets in the treatment of acute ischemic stroke.
- Trial name
- XY03-EA (NCT05515393)
- Testing
- XY03-EA
- Where
- China
- Volunteers
- 420 people
- Sponsor
- Shijiazhuang Yiling Pharmaceutical Co. Ltd
Giant Cell Arteritis
Assessment of Giant Cell Arteritis Medical Practices in France
The purpose of this study is to describe medical practices in patients with GCA in terms of patient journey, diagnostic methods and specific GCA treatments since diagnosis.
- Trial name
- ARTEMIS (NCT03658889)
- Where
- France
- Volunteers
- 306 people
- Sponsor
- Chugai Pharma France
Cerebrovascular Accident
EARLY 3-months Aggrenox Treatment Started Within 24 Hrs of Ischemic Stroke Onset vs. After One Week 100 mg ASA
German stroke units are hesitating to use Aggrenox for secondary ischaemic stroke / transient ischaemic attack (TIA) prevention in a sub-acute treatment setting.
- Trial name
- NCT00562588
- Testing
- Aggrenox bid (ASA 25mg/Dipyridamole ER 200mg), ASA 100 mg qd
- Where
- Germany
- Volunteers
- 551 people
- Sponsor
- Boehringer Ingelheim
Acute Ischemic Stroke
SY007 in Patients With Acute Ischemic Stroke
This Phase 1b multiple center, randomized, double-blind, placebo-controlled study is a dose escalation trial evaluating the safety, tolerability, PK characteristics and efficacy of SY-007 after injection in acute ischemicstroke…
- Trial name
- NCT04891913
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Suzhou Yabao Pharmaceutical R&D Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.